Monday, 24 Feb 2020

You are here

Lyrica Fails in Sciatica Pain

Lyrica (pregabalin) was first approved in 2004 and since has been studied and approved for use in neuropathic pain (associated with diabetic neuropathy), postherpetic neuralgia, partial onset seizures, fibromyalgia and neuropathic pain with spinal cord injury. It is often used to manage chronic pain and neuropathic pain outside these indications.

Australian investigators published their findings in the NEJM last week showing that pregabalin was no better than placebo in treating leg pain associated with sciatics (acute or chronic). 

Patients (n=209) were randomized to either pregabalin at a dose of 150 mg per day (max adjusted to 600 mg per day) or placebo for 8 weeks. The primary outcome was the leg-pain using a 10-point scale at weeks 8 and 52. They also examined disability, back-pain intensity, and quality-of-life measures. Secondary measures demonstrated the same lack of effect.

There were 227 adverse events in the pregabalin group and 124 in the placebo group. Dizziness was more common in the pregabalin group than in the placebo group.

Pregabalin did not sufficiently reduce the leg pain of sciatica, short term or long term and was associated with a higher adverse event rate. 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Half of Opioids Rx Come from 1% of MDs

The BMJ reports that while most US providers are cautious in their prescribing, half of opioid prescriptions are written by 1% of providers.

Between 2003 and 2017, there was an annual average of 669495 providers prescribing 8.9 million opioid prescriptions.

In 2017, 1% of providers accounted for 49% of all opioid doses and 27% of all opioid prescriptions; that's nearly 1000 times more than the middle 1% of prescribers.

Domestic Abuse Linked to Fibromyalgia and Chronic Fatigue

Domestic violence was found to predispose to a higher risk of fibromyalgia and those developing chronic fatigue syndrome.

Researchers studied the association between intimate partner violence (IPV) with fibromyalgia and CFS, using a retrospective open cohort design of patients entered into the “The Heath Improvement Network” database between 1995 and 2017.

A Potential Biomarker for Chronic Fatigue Syndrome Patients

Myalgic encephalomyelitis/chronic fatigue syndrome affects at least 2 million people in the United States and bears tremendous overlap with fibromyalgia - both being difficult to diagnosis because the symptom complex is often unrecognized and these conditions have no biomarker test. 

NIH Conference Review of Chronic Fatigue Syndrome

The current issue of JAMA reviews recent advances on chronic fatigue syndrome, also known as myalgic encephalomyelitis/(ME/CFS), based on a 2-day conference held at the NIH in an April 2019. The NIH 2-day conference reviewed recent progress and new research in several areas described below.

Study Looks at Opioid Use After Knee Surgery

A small study looked at whether reducing the number of opioid tablets prescribed after knee surgery would reduce postoperative use and if preoperative opioid-use education would reduce it even more.